Elton Zeqiraj
Has grant
Wellcome Trust Senior Research Fellow and Professor of Structural Biology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Regulation of immune signalling via ubiquitin-mediated receptor degradation
Open Date: 2022-04-01
Close Date: 2027-03-31
Grant: Close
Assembly, activation and function of JAMM/MPN deubiquitylating complexes
Open Date: 2016-08-17
Close Date: 2021-08-16
Grant: Close
A structural and biochemical approach to understand the molecular mechanism of glycogen synthesis.
Open Date: 2010-10-01
Close Date: 2015-03-31
Grant: Close
Molecular mechanism of glycogenesis and structural studies of glycogen synthase regulation
Open Date: 2010-05-01
Close Date: 2013-04-30
Articles (5)
Inhibition of adenosine 5′-monophosphate (AMP)–activated protein kinase (AMPK) is under increasing investigation for its therapeutic potential in many diseases. Existing AMPK inhibitors are however limited, with poor selectivity and substantial off-target effects. Here, we provide mechanistic insights and describe the cellular selectivity of the recently identified AMPK inhibitor BAY-3827. A 2.5-Å cocrystal structure of the AMPK kinase domain with BAY-3827 revealed distinct features including a disulfide bridge between the αD helix Cys 106 and the activation loop residue Cys 174 . This bridge appears to stabilize the activation loop such that Asn 162 repositions the Asp-Phe-Gly (DFG) motif Phe 158 toward the C-terminal lobe, displacing His 137 and disrupting the regulatory spine, promoting an inactive kinase state. In hepatocytes, BAY-3827 blocked AMPK activator (MK-8722)–mediated phosphorylation of ACC1 and corresponding inhibition of lipogenesis. Transcriptome analysis revealed that BAY-3827 down-regulated ~30% of MK-8722–stimulated AMPK-dependent genes. We establish the molecular and cellular basis of BAY-3827’s selectivity and utility for delineating AMPK functions while highlighting its limitations.
Year:
2025
Both mouse double-minute 2 (MDM2), an E3 ubiquitin ligase, and its closely related paralog, MDM4, which lacks E3 activity, play central roles in cellular homeostasis. MDM-linked dysfunction is associated with an increased risk of oncogenesis, primarily through targeting the tumor suppressor protein p53 for ubiquitination and degradation. Recent studies have revealed multifaceted roles of MDM proteins that are p53 independent with implications for their oncogenic properties. This review aims to provide an overview of MDM2 and MDM4, by assessing gene and protein structure and implications for protein–protein interactions and functions in cell and animal physiology. We also explore MDM2 and MDM4 role(s) in angiogenesis, a critical feature of solid tumor growth and progression. Finally, we discuss the current landscape in the development of MDM2 and MDM4 inhibitors for cancer therapy.
Year:
2025
The adaptor protein, speckle-type BTB/POZ protein (SPOP), recruits substrates to the cullin-3-subclass of E3 ligase for selective protein ubiquitylation. The Myddosome protein, myeloid differentiation primary response 88 (MyD88), is ubiquitylated by the SPOP-based E3 ligase to negatively regulate immune signaling; however, the sequence rules for SPOP-mediated substrate engagement and degradation are not fully understood. Here, we show that MyD88 interacts with SPOP through a long degron that contains the established SPOP-binding consensus and an N-terminal site that we name the Q-motif. Based on the sequence similarity to MyD88, we show that additional substrates, including steroid receptor coactivator-3, SET domain-containing protein 2, and Caprin1, engage SPOP in this manner. We show that the Q-motif is a critical determinant of these interactions in mammalian cells and determine X-ray crystal structures that show the molecular basis of SPOP associations with these proteins. These studies reveal a new consensus sequence for substrate-binding to SPOP that is necessary for substrate ubiquitylation, thus expanding the sequence rules required for SPOP-mediated E3 ligase substrate recognition.
Year:
2025
Inhibition of AMP-activated protein kinase (AMPK) is under increasing investigation for its therapeutic potential in many diseases, including certain cancers. However, existing AMPK- inhibitors available as tool compounds are largely limited to compound C/dorsomorphin and SBI-0206965, both of which suffer from poor selectivity and off-target effects. Here we describe the structure-based molecular insights and cellular actions of a recently identified potent AMPK inhibitor, BAY-3827. Kinase selectivity profiling and sequence analyses of kinases that are highly or weakly inhibited by BAY-3827 uncovered key conserved residues involved in its inhibitory mechanism. A 2.5 Å co-crystal structure of the AMPK kinase domain (KD)-BAY-3827 complex and comparison with known KD-inhibitor structures, revealed an overlapping site in the ATP-binding pocket and an αC helix-out conformation. A distinct feature of the BAY-3827-bound state is the formation of a disulfide bridge between the αD helix Cys 106 and the activation loop residue Cys 174 . This bridge appears to stabilize the activation loop such that Asn 162 repositions the DFG motif Phe 158 toward the C-terminal kinase lobe, displacing His 137 and disrupting the regulatory spine, thereby promoting an inactive state. In hepatocytes, 2.5-5 μM BAY-3827, but not the structurally resembling inactive BAY-974, fully blocked AMPK activator (MK-8722)-mediated phosphorylation of ACC1 and corresponding inhibition of lipogenesis. Unbiased transcriptome analysis in MK- 8722-treated wild-type and AMPK-null hepatocytes revealed that 5 μM BAY-3827 downregulated >30% of MK-8722-stimulated AMPK-dependent genes. Based on its greater selectivity and potency substantiated by comprehensive structural and cellular investigations, BAY-3827 is a powerful tool to delineate AMPK functions. One-sentence summary We provide the mechanism of action of the potent and selective AMPK inhibitor BAY-3827, which blocks AMPK-dependent cellular functions.
Year:
2025
Deubiquitylases (DUBs) are crucial in cell signalling and are often regulated by interactions within protein complexes. The BRCC36 isopeptidase complex (BRISC) regulates inflammatory signalling by cleaving K63-linked polyubiquitin chains on Type I interferon receptors (IFNAR1). As a Zn 2+ -dependent JAMM/MPN DUB, BRCC36 is challenging to target with selective inhibitors. We discovered first-in-class inhibitors, termed B RISC molecular g lues (BLUEs), which stabilise a 16-subunit BRISC dimer in an autoinhibited conformation, blocking active sites and interactions with the targeting subunit SHMT2. This unique mode of action results in selective inhibition of BRISC over related complexes with the same catalytic subunit, splice variants and other JAMM/MPN DUBs. BLUE treatment reduced interferon-stimulated gene expression in cells containing wild type BRISC, and this effect was absent when using structure-guided, inhibitor-resistant BRISC mutants. Additionally, BLUEs increase IFNAR1 ubiquitylation and decrease IFNAR1 surface levels, offering a potential new strategy to mitigate Type I interferon-mediated diseases. Our approach also provides a template for designing selective inhibitors of large protein complexes by promoting, rather than blocking, protein-protein interactions.
Year:
2024
Collaborators (15)
William Critchley
Research Fellow
University of Leeds
Alessandro Datti
Scientist & Senior Lecturer
University of Perugia
Olga Göransson
-
Luca Busino
Associate Professor
University of Pennsylvania
John Scott
Director, Dark Kinase Drug Discovery Lab
Monash Institute of Pharmaceutical Sciences
Queen Saikia
University of Sheffield
Kei Sakamoto
Professor at University of Copenhagen
University of Copenhagen
Francesco Del Galdo
University of Leeds
Sreenivasan Ponnambalam
Reader in Human Disease Biology
University of Leeds
Francesca Chandler
Queen Mary University of London
Antonio N. Calabrese
Associate Professor
University of Leeds
Mark A Febbraio
MONASH UNIVERSITY
Alex Addinsall
Københavns Universitet
Roger Greenberg
Professor
University of Pennsylvania
Conchita Fraguas Bringas
Københavns Universitet
Make your next move.
Prepare your application
Review drafts before you send them.